@article{3a0b2bd513ab4df29af4323aa4ddf83c,
title = "PAR1 signaling regulates the retention and recruitment of EPCR-expressing bone marrow hematopoietic stem cells",
abstract = "Retention of long-term repopulating hematopoietic stem cells (LT-HSCs) in the bone marrow is essential for hematopoiesis and for protection from myelotoxic injury. We report that signaling cascades that are traditionally viewed as coagulation related also control retention of endothelial protein C receptor-positive (EPCR +) LT-HSCs in the bone marrow and their recruitment to the blood via two pathways mediated by protease activated receptor 1 (PAR1). Thrombin-PAR1 signaling induces nitric oxide (NO) production, leading to EPCR shedding mediated by tumor necrosis factor-α-converting enzyme (TACE), enhanced CXCL12-CXCR4-induced motility and rapid stem and progenitor cell mobilization. Conversely, bone marrow blood vessels provide a microenvironment enriched with activated protein C (aPC) that retains EPCR + LT-HSCs by limiting NO generation, reducing Cdc42 activity and enhancing integrin VLA4 affinity and adhesion. Inhibition of NO production by aPC-EPCR-PAR1 signaling reduces progenitor cell egress from the bone marrow, increases retention of bone marrow NO low EPCR + LT-HSCs and protects mice from chemotherapy-induced hematological failure and death. Our study reveals new roles for PAR1 and EPCR in controlling NO production to balance maintenance and recruitment of bone marrow EPCR + LT-HSCs, with potential clinical relevance for stem cell transplantation.",
author = "Cohen, {Shiri Gur} and Tomer Itkin and Sagarika Chakrabarty and Claudine Graf and Orit Kollet and Aya Ludin and Karin Golan and Alexander Kalinkovich and Guy Ledergor and Eitan Wong and Elisabeth Niemeyer and Ziv Porat and Ayelet Erez and Irit Sagi and Esmon, {Charles T} and Wolfram Ruf and Tsvee Lapidot",
note = "Procrlow mice were provided by F.J. Castellino (University of Notre Dame). F2r−/− and F2rl2−/− were provided by P. Andrade-Gordon (Johnson & Johnson). ThbdPro/Pro mice were provided by H. Weiler (Blood Center of Wisconsin). Anti-TACE prodomain antibody was provided by C. Blobel (Hospital of Special Surgery). We thank C.E. Dunbar (NIH) for critically reviewing this manuscript and R. Rotkopf (Weizmann Institute of Science) for assistance in data statistical analysis. This study was supported by the Israel Science Foundation (851/13), the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine and FP7-HEALTH-2010 (CELL-PID 261387) (T.L.) and NIH grants HL-31950, HL-60742, BMBF 01EO1003 and the Humboldt Foundation (W.R.). Contributions - S.G.C. designed and performed experiments, analyzed data and wrote the manuscript; T.I. helped design and execute experiments and analyzed data; S.C. performed experiments and analyzed data; C.G. performed experiments; A.L., O.K., K.G., A.K., G.L. and E.N. helped with experiments; Z.P. helped with imaging flow cytometry; E.W. and I.S. provided help and guidance in experiments related to TACE prodomain inhibitor and EPCR shedding mechanism; A.E. helped design eNOS and NO-related experiments; C.T.E. provided help and guidance in EPCR- and TACE-related experiments; W.R. designed experiments and wrote the manuscript; T.L. designed the research and wrote the manuscript.",
year = "2015",
month = nov,
day = "1",
doi = "https://doi.org/10.1038/nm.3960",
language = "الإنجليزيّة",
volume = "21",
pages = "1307--1317",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "11",
}